{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:58:50Z","timestamp":1790895530124,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/ftd.0000000000000008","type":"journal-article","created":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T19:17:24Z","timestamp":1387826244000},"page":"269-272","source":"Crossref","is-referenced-by-count":8,"title":["The Comparison of Brand-Name and Generic Formulations of Venlafaxine"],"prefix":"10.1097","volume":"36","author":[{"given":"Stefan","family":"Unterecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Proft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pfuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2165\/00003495-199549020-00010","article-title":"Venlafaxine: a review of its pharmacology and therapeutic potential in depression.","volume":"49","author":"Holliday","year":"1995","journal-title":"Drugs"},{"key":"R2-21-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archpsyc.57.5.503","article-title":"Evidence of the dual mechanisms of action of venlafaxine.","volume":"57","author":"Harvey","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R3-21-20210129","first-page":"123","article-title":". Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.","volume":"17","author":"Vlahiotis","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"R4-21-20210129","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1345\/aph.1P482","article-title":". Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.","volume":"45","author":"Wu","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R5-21-20210129","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","article-title":"Switching from brand-name to generic psychotropic medications: a literature review.","volume":"17","author":"Desmarais","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"R6-21-20210129","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","article-title":"The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.","volume":"25","author":"Borgherini","year":"2003","journal-title":"Clin Ther"},{"key":"R7-21-20210129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0269881107077373","article-title":". Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series.","volume":"21","author":"Van Ameringen","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R8-21-20210129","doi-asserted-by":"crossref","first-page":"958","DOI":"10.4088\/JCP.09m05315","article-title":". Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study.","volume":"70","author":"Chenu","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R9-21-20210129","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/bmc.1253","article-title":"Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study.","volume":"23","author":"Rajasekhar","year":"2009","journal-title":"Biomed Chromatogr"},{"key":"R10-21-20210129","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.clinthera.2009.11.025","article-title":". Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.","volume":"31","author":"Wright","year":"2009","journal-title":"Clin Ther"},{"key":"R11-21-20210129","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.clinthera.2010.11.002","article-title":". Relative bioavailability of two formulations of venlafaxine extended-release 75-mg capsules in healthy Brazilian male volunteers: a single-dose, randomized-sequence, open-label, two-period crossover study in the fasting and fed states.","volume":"32","author":"Homero de Souza Filho","year":"2010","journal-title":"Clin Ther"},{"key":"R12-21-20210129","first-page":"S234","article-title":". A double-blind, crossover study comparing generic and brand fluoxetine in the treatment of major depressive disorder.","volume":"3","author":"Bakish","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"key":"R13-21-20210129","first-page":"84","article-title":"Therapeutic inadequacy in spite of bioequivalency on replacing Fluctine with Fluocim.","volume":"131","author":"Albrecht","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"R14-21-20210129","first-page":"185","article-title":"Is generic fluoxetine effective J Affect Disord.","volume":"81","author":"Yu","year":"2004","journal-title":""},{"key":"R15-21-20210129","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/YIC.0b013e328337910b","article-title":". Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.","volume":"25","author":"Margolese","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"R16-21-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00005053-198702000-00009","article-title":"Severe nortriptyline intoxication due to change from a generic to a trade preparation.","volume":"175","author":"Dubovsky","year":"1987","journal-title":"J Nerv Ment Dis"},{"key":"R17-21-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","article-title":". Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.","volume":"24","author":"Reis","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R18-21-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0031-1301366","article-title":". The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions.","volume":"45","author":"Unterecker","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"R19-21-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":". AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R20-21-20210129","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","article-title":". CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.","volume":"31","author":"Shams","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"R21-21-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-200404000-00010","article-title":"Therapeutic drug monitoring of psychotropic drugs. TDM nouveau.","volume":"26","author":"Bengtsson","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R22-21-20210129","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/j.1875-9114.1996.tb03009.x","article-title":". Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.","volume":"16","author":"Klamerus","year":"1996","journal-title":"Pharmacotherapy"},{"key":"R23-21-20210129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":". Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database.","volume":"31","author":"Reis","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R24-21-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4236\/pp.2011.21004","article-title":"Gender differences in the pharmacokinetics of oral drugs.","volume":"2","author":"Del Carmen Carrasco-Portugaortugal","year":"2011","journal-title":"Pharmacol Pharm"},{"key":"R25-21-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.clpt.6100226","article-title":"The current state of knowledge on age, sex, and their interactions on clinical pharmacology.","volume":"82","author":"Schwartz","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R26-21-20210129","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1176\/ajp.135.12.1560","article-title":"Tricyclics, bioequivalence, and clinical response.","volume":"135","author":"Ostroff","year":"1978","journal-title":"Am J Psychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T02:50:54Z","timestamp":1716346254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201404000-00021"}},"subtitle":["A Therapeutic Drug Monitoring Analysis"],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000008","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}